Manjunath Balaram, MD
Child & Adolescent Psychiatry · Corpus Christi, TXNPI 1790042836
Payments from drug & device makers
What this record shows
Neuronetics, Inc. accounts for 66.0% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2023 at $1,726 and has fallen 91.5% since, to $147 in 2025.
Across 43 payments — averaging $55.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neuronetics, Inc.$2K
- Ironshore Pharmaceuticals Inc.$180
- Teva Pharmaceuticals USA, Inc.$127
- Tris Pharma Inc$115
- Corium, LLC$88
- Otsuka America Pharmaceutical, Inc.$66
- plus $238 from 6 others
What the payments were for
- Travel & lodging$1,30655%
- Food & beverage$1,08045%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neuronetics, Inc. | 3 | $1,574 |
| Ironshore Pharmaceuticals Inc. | 7 | $180 |
| Teva Pharmaceuticals USA, Inc. | 6 | $127 |
| Tris Pharma Inc | 6 | $115 |
| Corium, LLC | 5 | $88 |
| Otsuka America Pharmaceutical, Inc. | 4 | $66 |
| Collegium Pharmaceutical, Inc. | 3 | $64 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $58 |
| Alkermes, Inc. | 3 | $54 |
| Johnson & Johnson | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Lundbeck LLC | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,386 in reported general payments places this provider in the 85th percentile of 301 child & adolescent psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Temazepam | 26 | $3,110 |
| Clonazepam | 221 | $2,986 |
| Lisdexamfetamine Dimesylate | 12 | $2,952 |
| Eszopiclone | 92 | $2,070 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 41 | $1,358 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 19 | $1,226 |
| Alprazolam | 161 | $489 |
| Zolpidem Tartrate | 40 | $450 |
| Methylphenidate ErMethylphenidate Hcl | 12 | $413 |
| Quetiapine Fumarate | 18 | $392 |
| Lorazepam | 58 | $322 |
| Duloxetine Hcl | 13 | $250 |
| Mirtazapine | 13 | $166 |
| Sertraline Hcl | 20 | $152 |
| Olanzapine | 12 | $128 |
Paid to pharmacies, not to this prescriber.
Other child & adolescent psychiatry in Corpus Christi
- Alain KaticBellaire$106K
- Steven PliszkaSan Antonio$59K
- Mary Garcia HolguinSan Antonio$24K
- John SteffekSpring$14K
- Robert MosquedaEdinburg$13K
- Gloria BrunGreenville$10K
- Mudassar TariqSugar Land$9K
- Charles PryzantDallas$9K
- Mehvesh AfrinaPlano$8K
- Kishore SunkaraHurst$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.